GlassScriptPhysician profile
Abhisekh Sinha Ray
NPI 1659620698
$2,213.18
in general payments reported to CMS, 2019-2025
34 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $183 · 2021: $245 · 2022: $206 · 2023: $199 · 2024: $471 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203 · Education: $83.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.56 |
| Education | $83.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $327.46 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $200.06 | 2019-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $174.21 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $163.91 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $147.47 | 2019-2024 | Farxiga |
| Travere Therapeutics, INC. | $136.29 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $99.53 | 2024 | |
| Mallinckrodt Hospital Products INC. | $83.15 | 2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $77.44 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $77.34 | 2019-2024 | Ultomiris |
| Biomerieux INC | $76.42 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.04 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $63.66 | 2021-2025 | Arexvy, Shingrix |
| Calliditas Therapeutics US INC. | $61.16 | 2023-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $56.27 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $41.43 | 2019-2021 | |
| Lilly USA, LLC | $38.79 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $30.57 | 2019 | |
| Gilead Sciences, INC. | $30.14 | 2022 | |
| Genentech USA, INC. | $29.30 | 2025 | Ocrevus Zunovo |
| Chiesi USA, INC. | $25.34 | 2022 | |
| Genzyme Corporation | $19.64 | 2024 | |
| Aurinia Pharma U.S., INC. | $19.13 | 2024 | Lupkynis |
| Jazz Pharmaceuticals INC. | $18.39 | 2022 | |
| Averitas Pharma INC. | $17.02 | 2023 | Qutenza |
| Philips North America LLC | $16.10 | 2019 | |
| Octapharma USA, INC. | $15.58 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.29 | 2021 | |
| Acadia Pharmaceuticals INC | $14.01 | 2021 | |
| Tanabe Pharma America, INC. | $13.59 | 2021 | |
| Electromed, INC. | $13.36 | 2019 | |
| Angiodynamics, INC. | $13.28 | 2019 | |
| Novo Nordisk INC | $13.27 | 2021 | |
| Pfizer INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhisekh Sinha Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.